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ABSTRACT
Over the last 25 years, allogeneic hematopoietic stem cell transplantation (HSCT) has been used increasingly as
a curative treatment option for patients with hematologic and neoplastic diseases. Despite major advances in
transplant immunology and improvements in supportive and critical caremedicine, HSCT is still plagued by sev-
eral life-threatening complications. As such, the establishment of effective therapeutic options for these compli-
cations will be crucial as increasing numbers of high-risk transplants are performed each year. This brief review
will discuss the contribution of vascular endothelial cell activation and injury to inflammation and end-organ
toxicity that occurs following allogeneic HSCT, and will highlight translational research efforts that have paved
the way to the development of novel strategies to treat and prevent disease. Finally, we will discuss in detail the
clinical manifestations and challenges encompassed by the syndrome of thrombotic microangiopathy following
HSCT.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative therapeutic option for
a number of malignant and nonmalignant disorders.
Unfortunately, HSCT is associated with several life-
threatening complications. Specifically, the develop-
ment of graft-versus-host disease (GVHD), idiopathic
pneumonia syndrome (IPS), veno-occlusive disease/si-
nusoidal obstruction syndrome (VOD/SOS), and
thrombotic microangiopathy (TMA) are associated
with significant morbidity and mortality, and limit
the ultimate success of HSCT, particularly when
full-intensity conditioning is administered. The estab-
lishment of effective strategies to reduce toxicity after
HSCT is critical as increasing numbers of high-risk
transplants are performed each year.The development of such approaches is fundamen-
tally dependent upon a basic understanding of patho-
physiologic mechanisms of disease. To this end,
a significant body of experimental and clinical data
has enhanced our knowledge as to how both cellular
and soluble effectors contribute to the pro-inflammatory
milieu that is associated with acute toxicity following
allogeneic HSCT. Endothelial cell (EC) damage is ob-
served in this setting, and has been implicated as a direct
contributor to the development of several complica-
tions including GVHD, VOD, TMA, and endothelial
leak syndrome (ELS) [1-3]. Support for this hypothesis
has been provided by clinical studies that have mea-
sured various markers of endothelial damage such as
soluble thrombomodulin, plasminogen-activator in-
hibitor, von Willebrand’s factor, and soluble ICAM-123
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have also demonstrated that EC respond to stimuli
such as irradiation, lipopolysaccharide (LPS), and
tumor necrosis factor-alpha (TNF-a) (all of which
are operative early after HSCT), by either becoming
activated or undergoing programmed cell death, or
apoptosis [7,8].
Cellular and soluble inflammatory effectors are
known to play a role in the major complications after
allogeneic HSCT including GVHD and IPS, and may
also contribute to others like VOD, but the molecular
mechanisms by which inflammatory proteins and
white blood cells (WBCs) gain access to ‘‘target’’ or-
gans and cause damage have yet to be fully elucidated.
Capillary permeability is a tightly regulated feature of
the microcirculation in all organ beds and is funda-
mentally altered in inflammatory conditions, resulting
in net extravasation of fluid out of the vascular space
and into tissues. Endothelial barrier integrity is be-
lieved to result from a balance between contractile
forces within ECs that create intercellular gaps and
adhesive forces between ECs that restrict such gaps;
an increase in contractile force within ECs is associ-
ated with increased permeability, whereas approaches
that decrease this effect reduce capillary permeability.
The passage of donor cells across the vascular endo-
thelium and into inflamed tissues is also tightly con-
trolled. This process is regulated in part by the
expression of adhesion molecules on endothelial sur-
faces and ultimately by the integrity of the endothelial
barrier itself. The recruitment of leukocytes from the
vascular space and into target tissue can be divided
into 4 steps: (1) weak adhesion of WBCs to the vascu-
lar endothelium, (2) firm adhesion of WBCs to endo-
thelial cells, (3) transmigration of leukocytes through
the vascular wall, and (4) migration of cells through
the extracellular matrix along a chemotactic gradient.
Thus, vascular ECs are the primary barrier separating
donor-derived leukocytes and allogeneic target tissue.
Injury to the vascular endothelium has been recently
observed early in the development of experimental
IPS [9] and identified as the initial target of an alloge-
neic GVH response elicited in SCID mice [2]. Taken
together, it is possible that diffuse microvascular
injury represents a common pathology underlying
many transplant-related complications, and this possi-
bility can help to explain the close clinical association
observed between TMA/ transplant-associated micro-
angiopathy (TAM) (discussed in detail later) and
GVHD, VOD/SOS, and infection.
IPS
Pulmonary complications occur in 25% to 55% of
transplanted patients, and account for approximately
40% of treatment-related mortality (TRM). In ap-
proximately 50% of these cases no infectious etiologyis identified, and this form of pulmonary dysfunction
has been defined as IPS [10]. IPS remains a frequently
fatal complication after allogeneic HSCT. Although
a recent study showed a lower incidence and earlier on-
set of IPS than previously reported, the typical clinical
course involving the rapid onset of respiratory failure
leading to death remained unchanged, underscoring
the critical nature of this transplant-related problem
[11]. Mortality rates therefore remain unacceptably
high, and the median time from diagnosis to death is
a sobering 14 days [11,12]. Potential etiologies for
IPS include direct toxic effects of HSCT conditioning
regimens, occult pulmonary infections, and immuno-
logic mechanisms as suggested by the association of
IPS with GVHD [10,13,14]. Clinical and experimental
data have shown that the intensity of HSCT condi-
tioning [15,16], along with inflammatory cytokine se-
cretion and the influx of donor derived cellular
effectors, may all contribute to the development of
IPS [17,18], but the mechanisms regulating leukocyte
recruitment to the lung in this context are not com-
pletely understood.
Clinical and experimental IPS are associated with
evidence for pulmonary vascular injury and leak as
demonstrated by pulmonary edema, enhanced total
protein levels in bronchoalveolar lavage fluid and in-
creased wet-to-dry lung weight ratios [18,19]. Excess
extravascular fluid in the lung impairs gas exchange
across the alveolar membrane and contributes to re-
ductions in lung compliance. However, the relation-
ship between vascular EC damage and lung injury
after HSCT has only recently been explored. Using
a well-described murine system [9], we recently dem-
onstrated that experimental IPS is associated with
EC injury and activation. Significant EC apoptosis ac-
companies pulmonary toxicity 6 weeks after allogeneic
HSCT when the extent of injury directly correlates
with the severity of lung histopathology. At this point,
pulmonary toxicity is robust, and approximately 40%
of all vessels in the lung are injured, and microscopic
inspection of these vessels reveal that most are sur-
rounded by a dense mononuclear cell infiltrate. Detec-
tion of apoptotic ECs was confirmed by cytologic
appearance, presence of activated caspase 3 in the cyto-
plasm, and TUNEL positivity of nuclei in allogeneic
tissue samples. Importantly, we also found that dam-
age to the endothelium occurs before maximal lung
histopathology is present; apoptotic endothelia are
readily apparent in the lung early after HSCT even
when leukocyte infiltration is at a very early stage.
In addition EC apoptosis is associated with evi-
dence for EC activation as measured by enhanced
mRNA expression of adhesion molecules, and with el-
evated BAL TNF-a levels. Finally, a causal relation-
ship between TNF-a and endothelial damage was
ultimately established; neutralization of TNF-a using
a soluble TNF-a binding protein (rhTNFR:Fc) from
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reduces EC apoptosis, and the progression of lung his-
topathology observed during this interval. We have re-
cently demonstrated that TNF-a production by both
donor T cells and accessory cells (monocytes and mac-
rophages) significantly contributes to the development
of IPS [19], but it remains to be determined whether
a subset of these infiltrating cells is also involved with
direct cell-mediated killing of ECs. Indeed, we have
shown that cytotoxicity via the Fas-FasL pathway con-
tributes to the development of experimental IPS [20],
but we have yet to extend these observations to EC in-
jury that occurs in this setting. Collectively, our results
demonstrate a role for vascular EC damage in leuko-
cyte recruitment during IPS and confirm a significant
contribution of TNF-a to each of these processes.
Our experimental findings are in accord with clin-
ical reports showing an association between microan-
giopathy and diffuse alveolar hemorrhage after
allogeneic HSCT; endothelial damage preceded pul-
monary toxicity in 3 of 4 patients [21]. Disruption of
pulmonary endothelial function is also observed dur-
ing sepsis-associated acute respiratory distress syn-
drome (ARDS), and a recent study explored the
mechanisms responsible for EC damage in this context
[22]. Angiopoietin-1 (Ang-1) and Ang-2 are peptide
ligands that bind the Tie-2 receptor tyrosine kinase
found that is primarily found on ECs. The 2 proteins
have been identified as an agonist/antagonist pair
that regulates early vascular development and endo-
thelial barrier integrity during physiologic homeosta-
sis and disease. Ang-2 is a known antagonist of the
Tie-2 that competitively binds the receptor and inter-
feres with agonistic Ang-1:Tie-2 receptor:ligand func-
tions. Moreover, Ang-2 release can be driven by
inflammatory stimuli such as TNF-a. By contrast,
Ang-1 activates Tie-2, resulting in receptor phosphor-
ylation and subsequent signal transduction that pro-
motes EC survival and vessel stability. Ang-1 may
also have an anti-inflammatory action by signaling
the downregulation of surface-adhesion molecules
such as VCAM-1 and E-selectin.
Parikh and colleagues [22] tested the hypothesis that
Ang-2 contributes to the disruption of the pulmonary
vascular endothelial barrier during sepsis-associated
lung injury. They found that circulating Ang-2 is signifi-
cantly elevated in humans with ARDS from sepsis, and
sera from these patients disrupt endothelial architecture
ex vivo. This disruptive effect correlated with measured
Ang-2 levels, wanes when sera collected during clinical
improvement is tested, and is reversed by Ang-1. In addi-
tion, Ang-2 alone can reproduce endothelial damage ex
vivo, and its administration to healthy mice results in pul-
monary capillary leak and edema. These findings suggest
that an imbalance in Tie-2 signaling could also arise in the
inflammatory milieu that characterizes the immediate
post-HSCT period. Because the expression of Tie-2 inquiescent adult tissues is highest in the lung, it is possible
that such an imbalance may preferentially affect the lung
in this context. Studies to explore this possibility in the
setting of IPS are currently ongoing.
Finally, laboratory insights regarding the role of
TNF-a in the development of IPS are being translated
back to the clinic. Recent work from the University of
Michigan and the Dana Farber Cancer Institute sug-
gests that etanercept (Enbrel, Amgen Corp, Thousand
Oaks, CA) may be a useful therapeutic option for IPS.
Etanercept was administered in combination with sys-
temic steroids to a total of 18 patients with IPS [23].
Etanercept was given subcutaneously at a dose of 0.4
mg/kg twice weekly for a maximum of 8 doses. Ther-
apy was well tolerated overall. Thirteen of 18 patients
were able to completely withdraw from supplemental
oxygen support within 28 days of therapy. Survival at
day 28 and day 56 (from the first etanercept dose)
was 73% and 60%, respectively. Based upon these en-
couraging results, larger phase II (pediatric) and phase
III (adult) trials are currently ongoing through the
Children’s Oncology Group (COG) and the BMT
clinical trials network (CTN), respectively.
ACUTE GVHD (aGVHD)
GVHD is the major cause of morbidity and mor-
tality following allogeneic HSCT. The onset of
aGVHD is usually within the first several weeks fol-
lowing the infusion of stem cells, and classically in-
volves immune-mediated damage to the skin, liver,
and gastrointestinal tract. Recently, clinical and exper-
imental data suggest that the lung may also be a target
organ, with disease manifesting itself as IPS (described
above). The pathophysiology of aGVHD is complex,
and is now known to involve aspects of both the adap-
tive and innate immune responses. Advances in basic
transplant immunology have demonstrated how inter-
actions between cells of the lymphoid and myeloid lin-
eage are governed by cytokines, and much recent
research has focused on the role of these cellular and
soluble effectors in the pathogenesis of aGVHD.
The pathologic findings of aGVHD characteristically
include epithelial damage that is usually apoptotic in
nature. Although vascular endothelia represent the
primary barrier between donor-derived cells, their se-
cretory products, and allogeneic target tissue, the role
of ECs in the development of GVHD has yet to be
fully appreciated.
When microvascular damage occurs in patients
after HSCT, it is difficult to recognize what is linked
to radiotherapy, to chemotherapy, or to immune dam-
age. Several lines of investigation have added to our
understanding of how ECs regulate immune-mediated
responses during both allograft and xenograft rejection
[9]. As noted, vascular endothelial cells are the primary
barrier separating the engrafting, donor-derived,
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as such, represent the first allogeneic cells encountered
by primed T cell effectors. Microvascular ECs can
express MHC Class I, MHC Class II, and minor histo-
compatibility (H) antigens, and the expression of these
molecules is enhanced by TNF-a and interferon-
gamma (IFN-g). It is conceivable, therefore, that
ECs can serve as targets for direct cell-mediated dam-
age. When cocultured with recipient type endothelium
in vitro, activated allogeneic T cell effectors enhance
mRNA expression of TNF-a, adhesion molecules
like ICAM-1, and cause EC injury [24].
Using an unirradiated animal model of splenocyte
transfer in immunodeficient mice wherein characteris-
tic epithelial damage in the GVHD target organs is
consistently reproduced, Dr. Janin and colleagues [2]
were able to assess EC damage induced solely by allo-
geneic reactions. Janin’s group of investigators found
that ECs were targets of the allogeneic reaction,
because no damage was found in mice following sple-
nocyte transfer from syngeneic donors. In addition,
the severity of endothelial injury was linked to the
amount of allogeneic splenocytes injected, and the
most severe damage led to rupture of the microvessel
wall and pericapillary hemorrhage, but not to throm-
bosis. The team also determined that ECs underwent
apoptosis through the Fas/FasL pathway; splenocytes
from FasL-deficient mice did not induce injury, and
the development of EC lesions was blocked by an
inhibitor of caspase (zVAD) and by injections of anti-
Fas antibodies. Importantly, endothelial damage oc-
curred before epithelial damage in the targets organs,
thereby identifying disseminated EC apoptosis as the
earliest target of an allogeneic GVH response in
several tissues [2].
Systematic analyses of microvessels in human
biopsies also reveal that EC damage is present in the
gut and skin. EC apoptosis in the digestive tract of
patients with aGVHD and the number of apoptotic
cells was linked to the severity of GVHD, leading to
transmural microvascular lesions and pericapillary
hemorrhage in the more severe cases. In patients
with chronic GVHD (cGVHD), another European
team performed a quantitative study of endothelial
cell surface and found a reduction of endothelial areas
in patients with cGVHD. Taken together, these clini-
cal and experimental data suggest that endothelial cell
damage in GVHD could lead to a ‘‘disappearing
microvessel syndrome,’’ as bile duct epithelial damage
leads to a ‘‘disappearing bile duct syndrome’’ common
to cGVHD, chronic liver allograft rejection, and pri-
mary biliary cirrhosis.
Evidence for EC damage in the context of GVHD
has also been provided by other clinical studies. Endo-
thelial microparticles (EMP) are vesicles shed from the
membrane of ECs upon activation of apoptosis, and
are thus good markers for endothelial stress [25].EMPs are also believed to promote disseminated
platelet aggregation and microangiopathy and to
have pro-inflammatory effects because they can bind
and activate monocytes, thereby stimulating release
of cytokines that may further damage the endothelium
[25]. It is interesting to note that in a recent study
where EMP levels were analyzed in 19 patients after
HSCT, EMP levels were significantly higher in
patients who had aGVHD compared to those without
aGVHD [26]. Whether these endothelial microparti-
cles play a significant role in the pathogenesis of other
complications after HSCT remains to be elucidated.
Vascular endothelial growth factor (VEGF) is
a member of a family of 6 structurally related proteins
that regulate the growth and differentiation of multiple
components of the vascular system, especially blood and
lymph vessels. VEGF (specifically VEGF-A) stimulates
vascular EC growth, survival, and proliferation, and is
important for endothelial integrity and tissue repair.
Nachbaur and colleagues [27] recently retrospectively
measured endogenous VEGF serum levels in seventy al-
logeneic HSCT recipients. VEGF levels were signifi-
cantly decreased within the first 2 weeks after the
HSCT, but returned toward pretransplant levels by
day115. At this time, higher levels (as determined using
the median value as a cutoff) were associated with less
TRM, faster neutrophil recovery, a lower incidence of
severe aGVHD, and significantly improved overall sur-
vival (OS). These findings are in accord with a similar
study that showed that low VEGF levels after allogeneic
HSCT are associated with non-relapse mortality
(NRM) with increased incidence and severity of
aGVHD [28]. Taken together, experimental and clinical
data suggest that EC damage and levels of proteins that
are critical to vascular endothelial integrity and tissue re-
pair may participate in the development of aGVHD.
VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION
SYNDROME (VOD/SOS)
Recently, a role for endothelial activation and in-
jury has been implicated in the pathogenesis of
VOD/SOS. Markers of endothelial damage including
plasma thrombomodulin (TM), selectins, tissue factor
pathway inhibitor (TFPI), soluble tissue factor (sTF),
and plasminogen activator inhibitor (PAI-1) are ele-
vated in patients with VOD/SOS [29]. Thrombocyto-
penia with platelet refractoriness is common in
patients with established VOD/SOS, and although
this may be because of splenic sequestration from por-
tal hypertension, it may also reflect increased platelet
consumption through EC injury. Not surprisingly,
thrombopoietin and von Willebrand’s factor multi-
mers are often elevated, whereas factor VII levels are
generally depressed, suggesting activation of the coag-
ulation cascade with ongoing EC injury. In concor-
dance with this, investigators have demonstrated
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shortly after high-dose cytoreductive therapy, in pa-
tients who subsequently develop VOD/SOS, whereas
there appears to be fluctuation in levels of procoagu-
lant proteins, including serum proteases and fibrino-
gen, and fibrin breakdown products, such as D-dimer
at similar time points.
Based upon the histopathologic findings of micro-
thrombosis and fibrin deposition that are present dur-
ing VOD/SOS, and the mechanisms of injury that may
be operative in the development of disease, several
therapeutic approaches have been explored. The ma-
jority of treatment strategies have focused upon fibri-
nolytic therapy with or without anticoagulation.
Unfortunately, approaches utilizing heparin, anti-
thrombin III (AT III), prostaglandin E1 (PGEI), and
activated protein C have been associated with limited
response rates and significant bleeding complications.
Defibrotide (DF), a polydisperse oligonucleotide with
a molecular weight of 23 kD [30], is an agent that mod-
ulates EC injury without enhancing bleeding or com-
promising the antitumor effects of cytotoxic therapy
[31]. DF binds specifically to the vascular endothelium
via adenosine receptors A1 and A2, which are part of
the growing family of nucleotide receptors involved
in EC regulation adhesion and response to injury.
DF has antithrombotic, anti-ischemic, anti-inflammatory,
antiadhesive, and thrombolytic properties, without
significant, anticoagulant activity. Recent studies of
human-derived, LPS-exposed microvascular and
macrovascular endothelium have shown preferential
protective effects of DF toward microvascular injury
[31].
Nonrandomized clinical trials using DF for the
treatment of severe VOD/SOS and multi-organ fail-
ure (MOF) following HSCT have been associated
with minimal toxicity, resolution of hyperbilirubine-
mia, and MOF and a corresponding improvement
in day 100 survival in a significant number of patients
[32]. In the largest experience reported to date,
where 88 HSCT patients with severe VOD/SOS
and MOF were treated with DF, complete response
was 36% and OS at day 1100 was 35% (versus
\10% expected) [32]. Predictors of survival included
younger age, autologous HSCT, and abnormal por-
tal flow, whereas busulfan-based conditioning and
encephalopathy predicted worse outcome. Decreases
in mean creatinine and PAI-1 levels during DF ther-
apy also predicted better survival, suggesting that
certain features associated with successful outcome
could correlate with DF-related treatment effects.
DF also appears to be effective in VOD/SOS follow-
ing Mylotarg therapy. Prospective, multicenter trials
of DF in the prevention and treatment of severe
VOD/SOS are now underway in the United States
and Europe, and preliminary results have been
encouraging.HSCT-ASSOCIATED THROMBOTIC MICROANGIOPATHY
Clinical syndromes presenting with microangio-
pathic hemolytic anemia, consumptive thrombocytope-
nia, often with renal insufficiency and encephalopathy,
have long been recognized as dangerous complication
following autologous and allogeneic HSCT. In the lit-
erature, the terms used to describe these microangio-
pathic processes have included hemolytic uremic
syndrome (HUS), microangiopathic hemolytic anemia
(MAHA), and thrombotic thombocytopenic purpura
(TTP). The BMT Clinical Trials Network (CTN)
has proposed the term TMA associated with transplan-
tation to encompass these HSCT-related HUS/TTP
syndromes. Similarly, the International Working
Group from the EBMT recommended TAM as an um-
brella term to cover these microangiopathic processes.
Although the proposed definitions for ‘‘TMA’’ and
‘‘TAM’’ vary to a certain extent, such efforts from recog-
nized groups like the CTN and IWG are essential, and
should provide a framework for future clinical and lab-
oratory research into this important, yet poorly under-
stood complication of transplantation. In deference to
both definitions, the combined terminology ‘‘TMA/
TAM’’ will be used in this review.
Clinical Features of TMA/TAM
The classic presentation of TMA/TAM includes
the relatively acute onset of anemia and thrombocyto-
penia with evidence of RBC fragmentation on the pe-
ripheral blood smear. This is invariably associated with
a rapid increase in the serum lactate dehydrogenase
(LDH) level. Almost all patients with TMA/TAM
will be thrombocytopenic, and many patients who de-
velop TMA/TAM early after HSCT will present with
a failure of the platelet count to rise appropriately [33].
Concomitant acute renal dysfunction, often associated
with proteinuria and hypertension, occurs in a majority
of patients. Neurologic deficits, including, but not re-
stricted to, confusion and seizures, occur in up to half
the cases. The onset of TMA/TAM usually occurs
within the first 100 days after HSCT, and the median
time of onset ranged from 44 to 67 days in 2 large ret-
rospective reports [34,35]. It is worth noting, however,
that there is a distinct subset of TMA/TAM that oc-
curs later and is more exclusively associated with renal
impairment. These later occurring TMA/TAM syn-
dromes, commonly referred to in the literature as
HSCT nephropathy, radiation nephritis, or condition-
ing associated HUS, can develop several months to
years after HSCT [36].
Recent reports have also shown that TMA/TAM
can affect the intestines and present with abdominal
pain and bloody diarrhea, thereby imitating enteric
GVHD or infectious colitis [37]. Diagnosis of intesti-
nal TMA relies primarily on histopathologic evalua-
tion demonstrating hyaline thrombi in capillaries of
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arteriolar lesions in the intestine on autopsy [37].
Many of these intestinal TMA cases were, in fact, de-
tected by intestinal biopsy when patients developed
increasing bloody diarrhea despite resolving skin
GVHD after therapy with corticosteroids.
Incidence of TMA/TAM
TMA/TMA after HSCT may be part of a spectrum
of transplant-related toxicities, including VOD/SOS,
GVHD, and IPS which, as discussed above, are associ-
ated with injury to the vascular endothelium. Research
efforts in TMA/TAM have been hampered by the
absence of a unified set of diagnostic criteria. Reflec-
tive of this problem, the reported incidence of this
complication in the HSCT literature has varied from
0.5% to 76% [33-35]. TMA/TAM occurs less fre-
quently after autologous HSCT (up to 2.6%) com-
pared to the allogeneic setting where the incidence is
generally closer to 10% [34]. Indicative of the lack of
a unified definition for this condition, a recent review
found 28 different sets of diagnostic criteria used in
35 publications. The most frequently cited criteria
required for diagnosis were: red cell fragmentation
(31 of 35), elevated LDH (25 of 35), platelet decline
(18 of 35), renal insufficiency (17 of 35), and neuro-
logic dysfunction (8 of 35).
Diagnostic Criteria for TMA/TAM
Recognizing the need to standardize definitions
for toxicity reporting in multicenter clinical trials and
facilitate future clinical investigative efforts, the
BMT CTN and EBMT IWG have recently proposed
their own sets of clinical criteria for reporting micro-
angiopathy associated with transplantation (Table 1)
[35,38]. The BMT CTN definition of TMA places
focus on the presence of red cell fragmentation (schis-
tocytosis) and elevation of serum LDH, in conjunction
with end-organ dysfunction manifested as either acute
renal or central nervous system (CNS) compromise
[38]. The IWG definition for TAM does not require
the presence of renal/CNS dysfunction, but requires
the presence of RBC fragmentation, reduced hapto-
globin, and increased LDH with prolonged/progres-
sive thrombocytopenia. By limiting the diagnosis to
patients with microangiopathy and concurrent renal/
CNS dysfunction, the CTN definition captures only
more severe cases of TMA/TAM (with organ damage)
compared to the broader IWG definition [35]. The
IWG placed particular focus on de novo or pro-
longed thrombocytopenia as a sine qua non for the
diagnosis of TAM, which concurs with the finding
in the review by George et al. [34], where low plate-
lets was the third most commonly cited criteria in the
literature. Because the CTN and IWG definitions of
TMA/TAM were conceived with distinct purposes inmind, they are expectedly different, although not mu-
tually exclusive, of each other. Both of these sets of
criteria deserve further testing and validation in large
clinical trials to assess their utility as a diagnostic and
prognostic tool.
Endothelial Cell Injury and TMA/TAM
The primary inciting events leading to the devel-
opment of TMA/TAM remain poorly understood,
but evidence suggests that damage to the vascular
endothelium is central to its pathogenesis. Direct sup-
port of this concept has come from scanning electron
microscopy showing EC damage in patients with
TMA/TAM [39]. As noted above, increased levels of
markers of EC injury/activation, including tissue
factor, von Willebrand’s factor antigen, thrombomo-
dulin, and PAI-1, have also been associated with
patients developing TMA/TAM, as well as other
transplant complications including VOD/SOS,
GVHD, and sepsis after allogeneic HSCT. Elevated
levels of inflammatory cytokines, including IL-1,
TNF-a, IFN-g, and IL-8 in patients with VOD/
SOS, GVHD, IPS, and sepsis may further contribute
to EC damage. These findings point to diffuse micro-
vascular injury as a common pathology underlying all
of these transplant complications, and may explain
the close clinical association observed between
TMA/TAM and GVHD, VOD/SOS, and infection
[34]. Proposed mechanisms leading to EC injury and
TMA/TAM posttransplant include direct toxicity
from high-dose conditioning, infection, GVHD or
a variety of medications, especially those used as
GVHD prophylaxis or treatment.
Table 1. CTN and IWGConsensus Criteria for Diagnosis of TMA/TAM
BMT CTN Toxicity Committee Consensus Definition for TMA
1. RBC fragmentation, $21 schistocytes per high-power field on
peripheral smear
2. Concurrent elevated serum LDH above institutional baseline
3. Concurrent renal* and/or neurologic dysfunction without other
explanations
4. Negative direct and indirect Coombs tests
International Working Group (IWG) definition for TAM
All the following are present:
1. Increased percentage (.4%) of schistocytes in the blood
2. De novo, prolonged or progressive thrombocytopenia (platelet
\5  109/l or $50% decrease from previous counts)
3. Sudden and persistent increase in LDH
4. Decrease in hemoglobin concentration or increased red blood
cell transfusion requirement
5. Decrease in serum haptoglobin concentration
*Doubling of serum creatinine from baseline (baseline 5 creatinine
before hydration and conditioning), or 50% decrease in creatinine
clearance from baseline.
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ine and tacrolimus, are directly toxic to endothelial
cells. CIs can also damage EC via secondary mecha-
nisms by triggering microvascular thrombosis. Siroli-
mus, a macrocyclic lactone antibiotic with immune
suppressive properties, has been used increasingly
following allogeneic HSCT as a therapeutic and pro-
phylactic agent against GVHD. Although Sirolimus
is in itself not associated with the occurrence of
TMA/TAM, its use in conjunction with calcineurin
inhibitors does potentiate the deleterious effects of
CI on the endothelium [40].
Risk Factors, Prognostic Factors, and Staging for
TMA/TAM
TMA/TAM has been associated with advanced
recipient age, female sex, unrelated or HLA-mis-
matched donor grafts, aGVHD, viral or fungal infec-
tions, and the use of CI, or Sirolimus in conjunction
with a CI [33,34,41]. Unfortunately, interpretation of
the literature is challenging, because most reports in-
clude small numbers of cases and use varying defini-
tions for the diagnosis of TMA/TAM. In the large
recent retrospective series involving 1219 allogeneic
transplants and 66 cases of TMA/TAM, significant
risk factors in multivariate analysis included female
gender, lymphoid malignancy, unrelated donors,
and aGVHD [41].
The clinical spectrum of TMA/TAM is highly var-
iable. According to the NCI Common Terminology
Criteria for Adverse Events (CTC AE) scoring system
(Table 2), clinical severity may range from grade 1 ‘‘ev-
idence of RBC destruction (schistocytosis) without
clinical consequence,’’ to a moderately severe problem
with concomitant renal insufficiency (grade 3), to
a life-threatening hemolytic anemia/thrombocytope-
nia with renal failure and/or devastating neurologic
complications (grade 4). In the review of the literature
review published by George et al. [34], the overall mor-
tality in 379 cases of TMA/TAM after allogeneic SCT
reported in 31 articles was 61%. A majority (81%) of
patients died within 3 months of the diagnosis of
TMA/TAM. Death may result directly from the se-
quelae of TMA/TAM such as acute renal failure, cere-
bral ischemia, and hemorrhage, or indirectly from
commonly associated disorders such as GVHD, infec-
tion, and VOD/SOS.
Clinical parameters associated with poor survival
in TMA/TAM include: age $18, unrelated or haplo-
identical donor, high LDH, high schistocyte count
(.5-10/hpf), and presence of nephropathy. Although
the literature suggests a number of factors that predict
worse survival in patients with TMA/TAM, there is in-
sufficient data to support any staging system for this
condition at this time. Until such a system is in place,
adverse vent reporting of TMA/TAM in HSCT clini-
cal trials should follow the guidelines specific to theclinical protocol, or default to the NCI Common Ter-
minology Criteria for Adverse Events v3.0 (Table 2)
for determination of severity.
Management of TMA/TAM
There is currently no standard treatment for
TMA/TAM following HSCT. There is, however,
a general consensus that once a diagnosis of TMA/
TAM is established, withdrawal of potential offending
drugs such as calcineurin inhibitors or Sirolimus
should be the primary intervention. In patients who
have or are at risk for GVHD, replacement of these
drugs with alternative immune suppressive agents are
necessary to mitigate GVHD exacerbation and further
endothelial damage from the GVH reaction. Aggres-
sive management of concurrent GVHD and infections
is crucial because these are common causes of mortal-
ity in patients with TMA/TAM. Despite its relative in-
effectiveness, many centers continue to include plasma
exchange (PE) in their management algorithm for pa-
tients with TMA/TAM, perhaps as a testament to the
Table 2. NCI Common Terminology Criteria for Adverse Events (CTC
AE) for TMA
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30 K. R. Cooke et al.lack of other viable treatments available. The fact that
TMA/TAM results from direct injury to ECs, and not
from circulating antibody, may explain the low re-
sponse rates to PE in this disease compared to classic
TTP; response rates for HSCT recipients with
TMA/TAM are generally less than 50%, and mortality
rates among patients treated with PE remain unaccept-
ably high [38].
As mentioned above, DF, a polydisperse oligonu-
cleotide that has protective effects on vascular endo-
thelium, has shown great promise in clinical trials as
a treatment for patients with hepatic VOD/SOS. Lim-
ited data exist currently for the use of DF in patients
with TMA/TAM after HSCT. Corti and colleagues
[42] have reported a series of 12 allogeneic HSCT pa-
tients treated with DF after the diagnosis of TMA/
TAM. Five patients had a complete response and 3
had a partial response. Complete responders included
3 of 10 patients who had ‘‘severe’’ disease, based on
the presence of neuropathy, nephropathy, gastroin-
testinal hemorrhage, or multiorgan failure. Further
investigation into the use of DF for patients with
TMA/TAM is indicated. The humanized monoclonal
antibody directed against CD20, rituximab, has been
reported in several small case series to have activity in
patients with relapsing or refractory TTP and HUS
[43-45], and Au and colleagues [46] recently reported
on 5 patients with TMA/TAM refractory to plasma
exchange and steroids who were treated with rituxi-
mab (375 mg/m2 twice a week  4). Four of 5 pa-
tients achieved a CR, and 3 remained in remission
with extended follow-up.
SUMMARY
TMA/TAM is an underrecognized, but often dev-
astating complication of HSCT especially in the allo-
geneic setting because of its close association with
calcineurin inhibitors, GVHD, and infections. Diag-
nosis of TMA/TAM is based on clinical criteria. The
recently proposed IWG and CTN definitions need
further validation, but should improve uniformity in
diagnosis and reporting of TMA/TAM across trans-
plant centers, and should facilitate future clinical trials.
Withdrawal of offending agents such as calcineurin in-
hibitors, supportive care, and aggressive management
of concurrent GVHD or infections, remain the stan-
dard treatment for patients with TMA/TAM. Plasma
exchange has demonstrated limited efficacy, and has
not been endorsed as a standard treatment. Measure-
ment of ADAMTS13 activity or testing for AD-
MATS13 inhibitors is not warranted during TMA/
TAM following HSCT because these levels do not
correlate with onset, severity, or response of therapy
in this disease. Based on its protective activity on mi-
crovascular endothelium and efficacy in hepaticVOD/SOS, DF should be a promising agent to inves-
tigate both as treatment and prophylaxis.
CONCLUSIONS
Over the last 25 years, the use of HSCT as a cura-
tive treatment option for patients with hematologic
and neoplastic diseases has steadily increased. Despite
major advances in transplant immunology and im-
provements in supportive and critical care medicine,
HSCT is still plagued by several life-threatening com-
plications. Specifically, the development of GVHD,
IPS, VOD/SOS, and TMA/TAM significantly limit
the ultimate success of HSCT, particularly in the
allogeneic setting when full-intensity conditioning is
administered. The establishment of effective therapeu-
tic options for these complications will be crucial as in-
creasing numbers of high-risk transplants are
performed every year. Further research into mecha-
nisms of injury incurred following HSCT should im-
prove our understanding of these disease processes.
To this end, clinical and preclinical data suggest
that injury to the vascular endothelium may contribute
to both the initiation and propagation of transplant-re-
lated complications, and demonstrate that EC apopto-
sis mediated by TNF-a and Fas-FasL is linked to the
pathogenesis of IPS and GVHD in experimental
models. Whether EC damage is a prerequisite for
GVHD, IPS, VOD/SOS, and TMA or develops as
a consequence of the cellular and inflammatory re-
sponse underlying these disorders remains to be fully
elucidated. It is likely, however, that EC damage con-
tributes to progressive disease in each setting, and
therefore conceivable that strategies that maintain
EC integrity may be effective at preventing or treating
each form of toxicity.
Combinatorial approaches aimed at identifying
patients at risk, minimizing conditioning-related in-
jury, and reducing the toxicity of HSCT without com-
promising graft-versus-leukemia activity or further
suppressing donor immunologic reconstitution, hold
promise in making allogeneic HSCT a more safe and
feasible option for a greater number of patients. Suc-
cess in these endeavors will require collaborative ef-
forts between basic laboratory programs and large
transplant centers to conduct robust prospective stud-
ies, with collection of tissue and blood samples for
translational research to identify the mechanisms of
endothelial injury crucial in the pathogenesis of these
feared transplant complications. Fortunately for our
HSCT patients, such trials are currently underway!
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